No
Non vérifié

Novo Nordisk A/S

Ce que nous écrivons

FinanceIndustrie pharmaceutiqueManagement/Organisation d'EntreprisePolitique ÉtrangèrePublicité/Marketing/Médias/Communication
13/11/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing
1.00
11/11/2026
Industrie pharmaceutique
Management/Organisation d'Entreprise
Médecine Santé Bien-être
Publicité/Marketing/Médias/Communication
Novo commits USD 200 million over 10 years to support the World Diabetes Foundation to strengthen diabetes prevention and care
1.00
03/11/2026
Industrie pharmaceutique
Management/Organisation d'Entreprise
Politique Étrangère
Novo raises full-year outlook on continued GLP-1 momentum, with third-quarter adjusted operating profit increasing 27% at CER to DKK 31,720 million
1.00
02/10/2026
Industrie pharmaceutique
Politique Étrangère
Novo provides update on the denecimig Biologics License Application (BLA) in the US
1.00
01/10/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026
1.00
22/09/2026
Industrie pharmaceutique
Management/Organisation d'Entreprise
Novo and UNICEF expand partnership to support a healthier start for more than 80 million children
1.00
21/09/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
1.00
21/09/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Highlights to be presented at Novo’s Capital Markets Day 2026
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0